ClinicalTrials.Veeva

Menu

Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan

Boehringer Ingelheim logo

Boehringer Ingelheim

Status

Completed

Conditions

Pulmonary Fibrosis

Treatments

Drug: pirfenidone
Drug: nintedanib

Study type

Observational

Funder types

Industry

Identifiers

NCT03242759
1199-0303

Details and patient eligibility

About

This is a non-interventional, multi-center study to collect data from patients with idiopathic pulmonary fibrosis (IPF) in clinical practice in Taiwan. The study will be carried out at 10 medical centers, the expert centers where IPF patients are mainly managed in Taiwan.

Enrollment

101 patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients can be included if ALL the following criteria are met:

    1.Newly diagnosed with IPF within 6 months based upon recent ATS/ERS/JRS/ALAT IPF guideline (Ref 1, Raghu G, et al. 2011).

  • Exclusion of other known causes of ILD (e.g. domestic and occupational environmental exposures, connective tissue disease, and drug toxicity).

  • Assessment of IPF based on HRCT or HRCT and surgical lung biopsy, if available. 2.Patient ≥ 20 years of age 3.Written informed consent prior to participation 4.Patients with further follow-up possible with participating physician during planned study period 5.Ability to read and write in the local language

Exclusion criteria

  • Patients should not be included if ANY of the following criteria is met:

    1. Lung transplantation expected within next 6 months.
    2. Inclusion in ongoing clinical trials.

Trial design

101 participants in 1 patient group

patients with idiopathic pulmonary fibrosis (IPF)
Treatment:
Drug: nintedanib
Drug: pirfenidone

Trial documents
2

Trial contacts and locations

10

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems